Patrys Limited (ASX: PAB) has advanced its RLS-2202 program toward clinical-stage development through the appointment of CMAX as the Phase 1A clinical trial site and Alithia Life Sciences as Contract Research Organisation (CRO). The appointments establish the operational framework required to commence the Company’s upcoming bridging study focused on safety, tolerability and pharmacokinetics of RLS-2202 in healthy volunteers.
CMAX, a specialised Adelaide-based Phase 1 clinical unit, will oversee participant dosing and monitoring, while Alithia will manage regulatory coordination, trial oversight, pharmacovigilance and operational execution. Management stated that both organisations were selected following a competitive review process based on their strong early-stage clinical development expertise and Phase 1 execution capabilities.
Patrys intends to submit its Human Research Ethics Committee application during Q2 2026 and, subject to approval, remains on track to begin participant dosing in Q3 2026. The Company’s RLS-2202 program targets delirium treatment in acute care settings through a proprietary injectable Quetiapine formulation designed for rapid and predictable therapeutic delivery.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Patrys Advances RLS-2202 Toward Phase 1 Clinical Trial with Key Clinical Appointments
Patrys Limited (ASX: PAB) has advanced its RLS-2202 program toward clinical-stage development through the appointment of CMAX as the Phase 1A clinical trial site and Alithia Life Sciences as Contract Research Organisation (CRO). The appointments establish the operational framework required to commence the Company’s upcoming bridging study focused on safety, tolerability and pharmacokinetics of RLS-2202 in healthy volunteers.
CMAX, a specialised Adelaide-based Phase 1 clinical unit, will oversee participant dosing and monitoring, while Alithia will manage regulatory coordination, trial oversight, pharmacovigilance and operational execution. Management stated that both organisations were selected following a competitive review process based on their strong early-stage clinical development expertise and Phase 1 execution capabilities.
Patrys intends to submit its Human Research Ethics Committee application during Q2 2026 and, subject to approval, remains on track to begin participant dosing in Q3 2026. The Company’s RLS-2202 program targets delirium treatment in acute care settings through a proprietary injectable Quetiapine formulation designed for rapid and predictable therapeutic delivery.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au